- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06692192
RIEPILOGO 2 sugli effetti comportamentali della psilocibina
Ruolo dell'esperienza, della consapevolezza cosciente e della plasticità negli effetti comportamentali della psilocibina - Studio di follow-up (studio RECAP 2)
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.
Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.
Participants will:
- Receive one of four possible combinations of medications
- Undergo an MRI
- Complete questionnaires
- Undergo transcranial magnetic stimulation (TMS) and EEG
- Volunteer for an open-label follow-up phase of study
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The purpose of this study is to investigate the role that inducing neuroplasticity plays in the behavioral effects of psilocybin in people with modest decrements in emotional wellbeing.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: RECAP Study Contact
- Numero di telefono: 608-263-4852
- Email: recap2@psychiatry.wisc.edu
Luoghi di studio
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53792
- Reclutamento
- UW School of Medicine and Public Health
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 18 to 65 years at screening, of any identified gender and racial/ethnic group
- Physically healthy; does not meet criteria for an exclusionary medical condition
- English-speaking (able to provide consent and complete questionnaires)
- Modest decrement in self-reported wellbeing without the presence of a DSM-5 Axis I mood or anxiety disorder
- Able to undergo magnetic resonance imaging (MRI) and transcranial magnetic stimulation (TMS)
Exclusion Criteria:
- Exclusionary DSM-5 psychiatric diagnosis and/or active suicidal ideation
- Exclusionary medical conditions
- Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)
- Clinically significant electrocardiogram (ECG)
- Use of psychotropic or CNS-altering medications within 3 months of screening
- Hypertension or tachycardia
Participants invited to participate in the 28-day open label follow-up phase will:
-
Fully complete all activities associated with the randomized phase, including the virtual Day 84 assessment, before being approached about participation in the open label phase.
-
Participants who meet stopping criteria during the randomized phase are not eligible to enroll in the open label phase.
-
Participants who withdraw from the randomized phase are not eligible to enroll in the open label phase.
-
Enrollment into the open label phase must occur in the following sequence:
- participants who have fully completed the randomized phase are screened for eligibility;
- eligible participants meet with the study team and provide informed consent for the open label phase;
- baseline eligibility is reassessed to confirm that participation in the open label phase remains appropriate and safe.
The Principal Investigator may decline or defer open-label enrollment when unresolved concerns make participation unsafe or scientifically inappropriate.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Group 1: Psilocybin and intravenous (IV) midazolam
Psilocybin (25 mg) + IV midazolam |
25mg of psilocybin
Altri nomi:
1mg of psilocybin
Altri nomi:
The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session. |
|
Sperimentale: Group 2: Psilocybin and IV saline
Psilocybin (25 mg) + IV saline (placebo for midazolam) |
25mg of psilocybin
Altri nomi:
1mg of psilocybin
Altri nomi:
Saline will be administered as a placebo for midazolam |
|
Sperimentale: Group 3: Psilocybin and IV midazolam
Psilocybin (1 mg/control) + IV midazolam |
25mg of psilocybin
Altri nomi:
1mg of psilocybin
Altri nomi:
The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session. |
|
Sperimentale: Group 4: Psilocybin and IV saline
Psilocybin (1 mg/control) + IV saline |
25mg of psilocybin
Altri nomi:
1mg of psilocybin
Altri nomi:
Saline will be administered as a placebo for midazolam |
|
Sperimentale: Exploratory Open Label Follow-Up Phase
Psilocybin (25 mg) |
25mg of psilocybin
Altri nomi:
1mg of psilocybin
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Warwick-Edinburgh Mental wellbeing Scale (WEMWBS)
Lasso di tempo: Baseline to 7 days post-dose
|
WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing. |
Baseline to 7 days post-dose
|
|
Change in Brief Experiential Avoidance Questionnaire (BEAQ)
Lasso di tempo: Baseline to 7 days post-dose
|
The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance |
Baseline to 7 days post-dose
|
|
Change in Probabilistic Reversal Learning (PRL)
Lasso di tempo: Baseline to 7 days post-dose
|
Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift). |
Baseline to 7 days post-dose
|
|
Change in transcranial magnetic stimulation evoked potential (TEP) amplitude
Lasso di tempo: Baseline to 7 days post-dose
|
TEP measures neural excitability in the stimulated region of the brain. |
Baseline to 7 days post-dose
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in WEMWBS
Lasso di tempo: Baseline to 28 days post-dose
|
WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing. |
Baseline to 28 days post-dose
|
|
Change in BEAQ
Lasso di tempo: Baseline to 28 days post-dose
|
The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance |
Baseline to 28 days post-dose
|
|
Change in PRL
Lasso di tempo: Baseline to 28 days post-dose
|
Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift). |
Baseline to 28 days post-dose
|
|
Change in TEP amplitude
Lasso di tempo: Baseline to 28 days post-dose
|
TEP measures neural excitability in the stimulated region of the brain. |
Baseline to 28 days post-dose
|
|
Altered States of Consciousness (ASC) questionnaire
Lasso di tempo: Dosing 1 day
|
Participants will complete a selection of several questions from the ASC questionnaire that strongly associate positively or negatively with later antidepressant effect of psilocybin in patients with treatment resistant depression or capture classic features of the psychedelic experience. During the dosing session, investigator will repeatedly ask selected items from the ASC scale to get a "real time" measure of what the participants are experiencing. Each of these items will be scored separately. Higher score are indicative of a more intense psychedelic experience. |
Dosing 1 day
|
|
Emotional Breakthrough Inventory (EBI)
Lasso di tempo: Dosing 1 day
|
The EBI is a 6-item scale that assesses the presence and severity of emotionally challenging/distressing experiences that occur during a psychedelic experience. Participants rate to what extent the statements apply to their experience by marking a single line across each scale. Scale ranges from not at all to very much so. Higher scores (more slashes toward the 'very much so' end) on the scale have been associated with enhanced well-being following psychedelic use |
Dosing 1 day
|
|
Psychological Insight Questionnaire (PIQ)
Lasso di tempo: Dosing 1 day
|
The PIQ is a 23-item instrument designed to query self-perceived attainment of insight during a psychedelic medicine session. Items are rated on a 6-point Likert scale, 0 = no not at all and 5 = extremely. Possible scares range from 0-115, with higher scores indicating greater insight. |
Dosing 1 day
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Charles Raison, MD, University of Wisconsin, Madison
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Alcaloidi
- Indoli
- Prodotti chimici inorganici
- Composti di cloro
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Benzazepine
- Benzodiazepine
- Triptamine
- Composti di sodio
- Cloruri
- Acido cloridrico
- Midazolam
- Psilocibina
- Cloruro di sodio
Altri numeri di identificazione dello studio
- 2024-0852
- A538900 (Altro identificatore: UW- Madison)
- SMPH/PSYCHIATRY/PSYCHIATRY (Altro identificatore: UW- Madison)
- Protocol Version 9/30/2026 (Altro identificatore: UW- Madison)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .